← Back to Search

Antisense Oligonucleotide

A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Participants With Chronic Heart Failure With Reduced Ejection Fraction (ASTRAAS-HF Trial)

Phase 2
Waitlist Available
Research Sponsored by Ionis Pharmaceuticals, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years

Summary

This trial tests a weekly under-the-skin shot called IONIS-AGT-LRX for people with a type of heart failure where the heart doesn't pump well. The treatment aims to lower specific proteins in the blood that affect heart function and fluid balance. The study will last several months and include up to 72 participants.

Eligible Conditions
  • Heart Failure

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: IONIS-AGT-LRxExperimental Treatment1 Intervention
IONIS-AGT-LRX by subcutaneous injection once-weekly
Group II: PlaceboPlacebo Group1 Intervention
Matching placebo by subcutaneous injection once-weekly
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
IONIS-AGT-LRx
2021
Completed Phase 2
~240

Find a Location

Who is running the clinical trial?

Ionis Pharmaceuticals, Inc.Lead Sponsor
150 Previous Clinical Trials
27,590 Total Patients Enrolled
~16 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top